Design Therapeutics reports Q2 net loss of $20.2M; modifies RESTORE-FA trial, delays FECD data

Design Therapeutics, Inc.

Net loss of $20.2M for Q2 2026; cash and securities of $207.4M at quarter-end.
RESTORE-FA trial modified: 12-week cohort at 1 mpk, primary endpoint endogenous FXN protein change; data expected Q1 2027.
Phase 1 MAD trial of DT-818 in DM1 initiated; data expected in 2027.
Phase 2 FECD trial of DT-168 delayed to 2027 due to supply issue with eye droppers.
Registrational plan update expected Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.